As Donald Trump rounds out his nominations for key positions in his incoming administration, we’re keeping an eye on how his health-related picks might impact the future of the psychedelics field, notably drug development and policy reform efforts.
Of course, many of Trump’s picks will presumably need to be confirmed, but we will leave coverage of that process to other reporters.
Here, we review some key nominees from the past week or so, including any mentions of psychedelics, of a handful of health-related nominees…
FDA Pick – Marty Makary
Perhaps the biggest recent nominee-related news was that Martin (‘Marty’) Makary has been tapped as the next FDA commissioner and is thus set to replace Robert Califf. Many mainstream scientists and researchers have let out a sigh of relief, seeing Makary as a more moderate appointee than RFK Jr…
To continue reading, please log in or join Pα+…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
